Distribution · MENA · Announced 21 Oct 2026
Enzymatica → MedonyX
Enzymatica signed a long-term exclusive deal with MMDS-backed MedonyX to register and sell its ColdZyme cold-symptom mouth spray, a CE-marked medical device, in Jordan and Iraq, its first MENA markets. Launch targeted for Q1 2027.
Parties: Enzymatica (Sweden) → MedonyX (MMDS) (Jordan)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- Jordan and Iraq; long-term exclusive distribution; launch expected Q1 2027 subject to approval
- Therapeutic area
- Respiratory
- Asset
- ColdZyme (enzyme-based mouth spray)
- Announced
- 21 Oct 2026
Our analysis
Why this matters
Swedish life-science company Enzymatica announced on 21 October 2026 a long-term exclusive distribution agreement with MedonyX, a Jordanian company backed by the healthcare and market-access firm MMDS. MedonyX will handle registration, marketing, sale and distribution of ColdZyme in Jordan and Iraq. Launch is expected in the first quarter of 2027, subject to local regulatory approval. Financial terms and the exact duration were not disclosed.
ColdZyme is an enzyme-based mouth spray that forms a protective barrier in the mouth and throat, intended to treat and relieve common cold and flu-like symptoms. It is a CE-marked Class III medical device under the EU Medical Device Regulation, not a medicine. Enzymatica describes the deal as its first step into the MENA region and says further partner discussions are under way market by market.
The full analysis is free to read with a work email on this page.